NeuroPace, Inc. is a medical device company in the United States. The company is headquartered in Mountain View, California.
| Revenue (TTM) | $99.53M |
| Gross Profit (TTM) | $77.93M |
| EBITDA | $-16.51M |
| Operating Margin | -25.20% |
| Return on Equity | -111.40% |
| Return on Assets | -10.00% |
| Revenue/Share (TTM) | $2.99 |
| Book Value | $0.43 |
| Price-to-Book | 38.14 |
| Price-to-Sales (TTM) | 6.10 |
| EV/Revenue | 5.7 |
| EV/EBITDA | -16.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -2.00% |
| Shares Outstanding | $34.09M |
| Float | $23.29M |
| % Insiders | 4.04% |
| % Institutions | 96.28% |
Volatility is currently expanding
The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offering upside despite near-term losses.
NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG data to speed ECoG review and insights.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive neuromodulation in epilepsy care, including long-term clinical out.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace's broader AI platform strategy, leveraging the world's only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed. ECoG Assistant: Treatment Insights Si.
NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.
NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.
NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.
NeuroPace raises revenue guidance for 2026 after Q1 sales beat estimates and losses narrow, driven by strong RNS System growth.
